Today The Allergan PLC. (AGN) Position Lowered by Tokio Marine Asset Management Co. Ltd.

Today The Allergan PLC. (AGN) Position Lowered by Tokio Marine Asset Management Co. Ltd.

Tokio Marine Asset Management Co. Ltd. reduced its stake in shares of Allergan PLC. (NYSE:AGN) by 11.2% during the third quarter, Holdings Channel reports. The institutional investor owned 10,212 shares of the company’s stock after selling 1,294 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Allergan PLC. were worth $2,352,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Livingston Group Asset Management CO operating as Southport Capital Management purchased a new position in Allergan PLC. during the second quarter valued at approximately $125,000. Carroll Financial Associates Inc. increased its position in Allergan PLC. by 68.7% in the third quarter. Carroll Financial Associates Inc. now owns 555 shares of the company’s stock valued at $127,000 after buying an additional 226 shares during the last quarter. Trust Co. of Vermont increased its position in Allergan PLC. by 17.1% in the third quarter. Trust Co. of Vermont now owns 638 shares of the company’s stock valued at $147,000 after buying an additional 93 shares during the last quarter. Integrated Investment Consultants LLC increased its position in Allergan PLC. by 10.3% in the third quarter. Integrated Investment Consultants LLC now owns 653 shares of the company’s stock valued at $152,000 after buying an additional 61 shares during the last quarter. Finally, High Point Bank & Trust Co. increased its position in Allergan PLC. by 3.6% in the third quarter. High Point Bank & Trust Co. now owns 717 shares of the company’s stock valued at $165,000 after buying an additional 25 shares during the last quarter. Hedge funds and other institutional investors own 87.74% of the company’s stock.

Shares of Allergan PLC. (NYSE:AGN) opened at 213.15 on Wednesday. Allergan PLC. has a one year low of $184.50 and a one year high of $301.32. The company has a market cap of $79.95 billion, a PE ratio of 5.98 and a beta of 1.02. The firm’s 50-day moving average is $205.02 and its 200-day moving average is $224.49.

Allergan PLC. (NYSE:AGN) last announced its quarterly earnings data on Wednesday, November 2nd. The company reported $3.32 earnings per share for the quarter, missing the Zacks’ consensus estimate of $3.65 by $0.33. The business earned $3.62 billion during the quarter, compared to analysts’ expectations of $3.73 billion. Allergan PLC. had a return on equity of 7.26% and a net margin of 93.74%. Allergan PLC.’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter last year, the company posted $3.48 EPS. On average, equities analysts anticipate that Allergan PLC. will post $13.39 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 28th. Stockholders of record on Tuesday, February 28th will be issued a dividend of $0.70 per share. This is a boost from Allergan PLC.’s previous quarterly dividend of $0.05. The ex-dividend date of this dividend is Friday, February 24th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.31%.

AGN has been the topic of a number of analyst reports. William Blair reissued a “market perform” rating on shares of Allergan PLC. in a research report on Monday, November 21st. Barclays PLC reissued an “equal weight” rating and set a $250.00 price target on shares of Allergan PLC. in a research report on Monday, October 31st. Credit Suisse Group reissued an “outperform” rating and set a $329.00 price target on shares of Allergan PLC. in a research report on Thursday, November 3rd. Morgan Stanley reduced their target price on Allergan PLC. from $300.00 to $274.00 and set an “overweight” rating on the stock in a report on Thursday, November 3rd. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and issued a $300.00 target price on shares of Allergan PLC. in a report on Tuesday, September 27th. Seven research analysts have rated the stock with a hold rating and twenty have issued a buy rating to the company’s stock. Allergan PLC. currently has an average rating of “Buy” and a consensus target price of $270.72.

In other news, CEO Brent L. Saunders purchased 5,250 shares of the business’s stock in a transaction dated Monday, November 21st. The shares were purchased at an average price of $189.13 per share, for a total transaction of $992,932.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Nesli Basgoz sold 500 shares of the stock in a transaction that occurred on Thursday, December 8th. The shares were sold at an average price of $188.72, for a total transaction of $94,360.00. The disclosure for this sale can be found here. Corporate insiders own 0.27% of the company’s stock.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Related posts

Leave a Comment